Established class (EPC)Cholinergic Muscarinic Antagonist
Mechanism of actionCholinergic Muscarinic Antagonists
DEA scheduleNon-controlled
Marketing categoryNDA
Marketing statusOn market
FDA listing statusListed (active directory)
Marketing start2016-01-01
RouteTRANSDERMAL
Dosage formPATCH
SubstanceOXYBUTYNIN
GPI-1454100045008720
GPI classOxytrol For Women
GCN Seq No071392
GCN35162
HICL code025056
Ingredient (HICL)Oxybutynin
HIC1 codeR
Therapeutic class — broad (HIC1)Kidney/Urinary Tract
HIC2 codeR1
Therapeutic class — intermediate (HIC2)Affect Primarily Kidneys/Urinary Tract
HIC3 codeR1A
Therapeutic class — specific (HIC3)Urinary Tract Antispasmodic/Antiincontinence Agent
AHFS code86:12.04.00
AHFS classAntimuscarinics
FDB label nameOXYTROL FOR WOMEN 3.9 MG/24HR
FDB brand nameOxytrol For Women
Legend statusO — Over-the-counter (OTC) drug or device
Why two NDCs?
The FDA registers this code as 0023-9637-08 — a 4-4-2 layout, and that's what's printed on the package and shown on DailyMed. For insurance claims, every NDC is standardized to a uniform 11-digit 5-4-2 format by adding a zero to the labeler segment → 00023-9637-08. Same drug, same package — only the format differs.
Where does this data come from?
Identifiers from the FDA openFDA NDC Directory and Structured Product Labeling; RxCUI from RxNorm (NLM); GPI from Medi-Span; GCN / HIC / AHFS / legend from First Databank.
🏷️RxNorm drug class
This medicine belongs to the Cholinergic Muscarinic Antagonist class.
Drug family (ATC)Drugs for urinary frequency and incontinence
How it worksCholinergic Muscarinic Antagonists
Where does this data come from?
Therapeutic classes from RxNorm RxClass (U.S. National Library of Medicine) — Established Pharmacologic Class (FDA), ATC drug family (WHO) and mechanism of action, matched by this product’s RxCUI.
The labeler markets the product; the application holder owns the FDA approval. They’re often the same company but can differ (e.g. a repackager or an authorized generic). A mailing address / phone appears here when the manufacturer includes it in the product’s FDA label (not all do).
Where does this data come from?
Labeler, application holder and registered establishment from the FDA openFDA NDC Directory and Drugs@FDA; address/contact from the product’s FDA label.
🩺 Clinical
Label name OXYTROL FOR WOMEN 3.9 MG/24HRIngredient Oxybutynin
📖 What it is MedlinePlus · NLM
Oxybutynin transdermal patches are used to treat an overactive bladder (a bladder condition that causes sudden urges to urinate that may be hard to control). Oxybutynin is in a class of medications called antimuscarinics. It works by relaxing the bladder muscles.
Oxybutynin calms down an overactive bladder by relaxing the bladder muscle and reducing those sudden, hard-to-ignore urges to go. Over time, most people find they have fewer urgent...
What exactly is oxybutynin supposed to do for me?
Yes, dry mouth is the most common side effect of oxybutynin — and it's more noticeable with the immediate-release tablets than the extended-release form. Sipping water throughout t...
My mouth is incredibly dry since starting this — is that normal?
Plain-language summary from MedlinePlus (U.S. National Library of Medicine); supplement & herbal interactions and nutrient depletion data from the Natural Medicines database; our full guide is HelloPharmacist editorial content.
💬 Questions about Oxybutynin?
Ask a licensed pharmacist directly — free, answered by our team.
Inactive ingredients, also called excipients, are components of the drug product
other than the active ingredient. They may include fillers, dyes, coatings, preservatives, flavors,
or other formulation ingredients.
💡 Tap an ingredient (hover on desktop) to see what it is and why it’s used.
UNII XHX3C3X673
Triacetin is a clear, oily liquid made from glycerin and acetic acid. It works as a plasticizer and solvent in medicines, helping soften coatings and improve how liquids mix together in formulations.
1 inactive ingredient listed in the exact product block matched to this NDC.
The official label also statesacrylic adhesive, polyester/ethylene-vinyl acetate film, siliconized polyester film, and triacetin
Label-section wording can be broader than the structured product block and may mention additional formulation ingredients.
Where does this data come from?
Data sourced from official FDA Structured Product Labeling (SPL) via DailyMed — ingredient classCode="IACT" elements from the exact product block matched by this NDC. Label-section narrative from DailyMed / the openFDA label index is shown separately when available.
Inactive ingredient FAQ
Are inactive ingredients the same for every manufacturer?
No. Inactive ingredients can differ by manufacturer, dosage form, strength, and package / product version.
Why might an inactive ingredient be missing?
Some SPLs do not provide a complete structured inactive-ingredient list, and older or unusual labels may only include the information in narrative text.
Can inactive ingredients matter?
Yes. They can matter for allergies, intolerances, dyes, gluten / lactose concerns, preservatives, and formulation differences — but confirm with a pharmacist or the manufacturer when it’s clinically important.
💲 Pricing
A drug doesn't have one price. Each row is a different public payment system, and none is what you'd pay at the counter — that depends on your insurance. The ⓘ on each row explains what it measures.
Price system
Per ea
Per package
Retail pharmacies payNADAC · weekly
$2.750
$87.99 / 32 patch
Medicaid paysCMS SDUD · 12 mo
$3.73
$119.24 / 32 patch
Medicare drug plans payPart D · quarterly
No Part D plan price is available for this NDC in our data.
NADAC price history (per ea) — tap or hover for the price & month
▲ Up 7% over the last 12 months.
Where does this data come from?
NADAC (National Average Drug Acquisition Cost) is the CMS weekly pharmacy-acquisition-cost survey — what pharmacies pay. ASP (Average Sales Price) is the CMS Medicare Part B drug-payment file, published quarterly. Medicaid pays is computed by us from CMS State Drug Utilization Data (total reimbursed ÷ units, trailing 12 months) — gross of rebates and inclusive of dispensing fees, so it reflects what Medicaid paid, not an acquisition cost. Medicare drug plans pay is the median negotiated point-of-sale unit cost across plans listing this NDC in the CMS quarterly Prescription Drug Plan pricing files, before rebates. The VA pays is the federal contract price (FSS, and the statutory Big 4 ceiling where listed) from the VA National Acquisition Center pharmaceutical price file. All are free public government data; each measures a different payer, so the figures are not directly comparable.
About this product: this is the brand-name version. Some generic versions are approved by the FDA, but we could not confirm current pharmacy availability from our pricing/market data.
Where does this data come from?
Equivalents are other NDCs of the same ingredient, form and route from the openFDA NDC Directory, ranked least-expensive-first by NADAC. Therapeutic-equivalence (AB) ratings come from the FDA Orange Book; biologics use the FDA Purple Book for biosimilar & interchangeable status.
⏳ Availability & generic status
🏛️
2016
On the market since
Jan 2016
📍
2026
Currently FDA-listed
10 years listed
🔒
·
Generic approved (availability unconfirmed)
see note
🔒Generic approved by FDA, but pharmacy availability is not confirmed
The FDA lists approved generic versions of this medicine, but that does not always mean a pharmacy can get one today. Patent rules, launch agreements, supply and pricing can affect when generics actually arrive.
Where does this data come from?
Patents and exclusivity from the FDA Orange Book (small-molecule drugs), refreshed from public FDA data. Generic launch timing is an estimate, not a guarantee.
🗺️ Medicaid utilization & spend
📍 This exact package only: Medicaid data is reported per full 11-digit NDC — labeler, product and pack size — so every number here is for 00023-9637-08, not the drug overall. Other pack sizes report separately.
💊 Pharmacy benefit only: These are Medicaid outpatient pharmacy claims, billed by NDC. They exclude the medical benefit — clinic- or hospital-administered drugs billed under HCPCS J-codes — so drugs used mostly that way (e.g. Avastin, Lucentis, Keytruda) can look low or missing here. That’s expected, not an error.
📅 Q1 2025 – Q4 2025 · 4 quarters of data
ⓘ The newest quarter is usually incomplete when first published; states restate recent quarters in later CMS releases, so the latest figures typically revise upward. State coverage-policy changes can also shift quarter-to-quarter totals.
Prescriptions last 4 qtrs
273
Units reimbursed last 4 qtrs
2.3K
Gross reimbursed last 4 qtrs
$8.7K
Avg / prescription
$31.75
Avg / unit
$3.7264
Latest quarter Q4 2025
56Rx
Medicaid pays / ea
$3.7264
gross reimbursed
vs
NADAC / ea
$2.7497
acquisition cost
=
Spread
+$0.9767
+36% vs cost
What Medicaid paid per ea (before rebates; includes the pharmacy’s dispensing fee) compared with NADAC — the average price pharmacies pay to buy the drug. A positive spread means Medicaid reimbursed more than the purchase price, before manufacturer rebates.
Fee-for-service vs managed care ⓘ
73% FFS27% MCO
Fee-for-service · 198 Rx Managed care · 75 Rx
State Medicaid map
Units reimbursed · per 100k residents
2.210.4
gray = no data reported ⓘ
Colors are per 100,000 residents, so big states don’t automatically dominate. Tap or hover a state for its actual totals.
Tap or hover a state
…for its Medicaid breakdown
Prescriptions—
Units—
Reimbursed—
🏆 Top states by units · per 100k residents
1Oregon10.4 /100k
2California4.2 /100k
3Ohio2.2 /100k
National units — by quarter
💵 About the dollar figures: “reimbursed” is what Medicaid paid pharmacies before confidential manufacturer rebates, so the program’s real net cost is lower than these numbers. Fee-for-service and managed-care claims are combined unless split above. Source: CMS State Drug Utilization Data; per-100k rates use 2023 Census population estimates.
💊 Medicaid utilization by pack size
Medicaid (SDUD) totals over the four most recent reported quarters for every package size of this drug — handy when a specific package (e.g. a starter/titration pack) carries little or no Medicaid volume on its own.
Drug total (last 4 qtrs): 273 Rx · 2,326 units · $8,668 gross reimbursed
Tap a pack size to open its page. Source: CMS State Drug Utilization Data, last 4 quarters.
📊 Medicare Part D spend CMS · PART D · 2026 (Q1)
Medicare Part D (outpatient prescription) spending for Oxytrol (matched by generic name) — the program that covers self-administered drugs. 1 manufacturer.
⚠️ Drug-level data: CMS publishes Part D spending by drug, not by NDC — these figures combine every manufacturer, strength and package size sold under the name Oxytrol. That’s a different level of aggregation than the Medicaid card above, which is specific to this exact 11-digit NDC (pack size included), so the two aren’t directly comparable.
Period
Total Part D spend
$232K
Claims incl. refills
259
Beneficiaries
149
Spend / beneficiary
$1,557.02
Spend / claim
$895.74
Trend by period
💵 About the dollar figures: spending is what Part D plans paid before confidential manufacturer rebates, so the program’s real net cost is lower. A blank patient count means fewer than 11 people — CMS hides counts that small to protect privacy. Source: CMS Medicare Quarterly Part D Spending by Drug (data.cms.gov), updated quarterly.
🔬 Reported adverse events (FAERS)
Read carefully: FAERS reports are voluntary and unverified. Counts are not incidence, do not establish causation, are subject to reporting bias, and cannot be used to compare one drug to another. Shown for signal context only. Reports for Oxytrol for Women (this brand).
Top reported reactions
Fatigue1,535
Fall1,448
Nausea1,204
Dizziness1,109
Diarrhoea1,096
Pain1,067
Urinary Tract Infection1,031
Age at onset
Neonate17
Infant6
Child43
Adolescent24
Adult1,535
Elderly1,869
Reporter sex
Male · 23%
Female · 77%
Unknown · 1%
Serious outcomes
Hospitalization6,707
Death1,674
Life-threatening620
Disabling562
Reports over time (by year) — tap or hover for the count & year
Most recent year is provisional (FAERS lags ~3 months).
Where does this data come from?
Adverse-event reports from the FDA Adverse Event Reporting System (FAERS) via openFDA. FAERS reports are voluntary and unverified — counts are not incidence and don’t establish causation.
16 PATCH in 1 CARTON (0023-9637-04) / 4 d in 1 PATCH
$2.75 / ea
$43.99
2016-01-01
Active
00023-9637-08 You're viewing this
32 PATCH in 1 CARTON (0023-9637-08) / 4 d in 1 PATCH
$2.75 / ea
$87.99
2019-10-01
Active
This pack effectively ties for the lowest per-ea cost of the 2 priced pack sizes ($2.75 NADAC).
In Medicaid, this is the most-dispensed pack of this product — about 100% of fills over the last four reported quarters. See all packs ↓
Pack size FAQ
What quantity is in NDC 00023-9637-08?
NDC 00023-9637-08 is listed by the FDA — 32 patch in 1 carton / 4 d in 1 patch.
What NDC number is used to bill for this package of Oxytrol for Women Oxybutynin 3.9 mg/d Patch?
Bill NDC 00023-9637-08 — the 11-digit billing format is 00023963708. Pharmacy and medical claims use the 11-digit form; the FDA label may print a shorter form of the same code.
Prices are the latest CMS NADAC pharmacy acquisition cost per NDC; per-pack figures are per-unit × pack quantity, shown only when the pack is denominated in the same measure NADAC prices.
📄 FDA label — Drug Facts FDA SPL
The complete FDA label for this product — the official Drug Facts labeling, verbatim, section by section. Jump with a chip, search within the label, or expand everything.
Use treats overactive bladder in women you may be suffering from overactive bladder if you have had 2 or more of the following symptoms for at least 3 months: ○ urinary frequency (the need to urinate more often than usual; typically more than 8 times in 24 hours) ○ urinary urgency (a strong need to urinate right away) ○ urge incontinence (leaking or wetting yourself if you cannot control the urge to urinate) non-drug therapies may also help you (see the consumer information leaflet inside the package)
⏱️Dosage and Administration212 words▾
Directions women 18 years of age and older: How to use the patch: open 1 pouch and apply patch immediately to a clean, dry and smooth area of skin on your abdomen, hips or buttocks. Do not put the patch on oily, damaged (cut or scraped), or irritated (rashes) skin. Do not put the patch on skin with oils, lotions or powders because that could keep the patch from sticking to your skin. wear patch under clothing, do not expose the patch to sunlight do not cut the patch into smaller pieces wear only 1 patch at a time for 4 days in a row after 4 days, remove the used patch and apply a new one change the patch every 4 days for as long as you use this product each time you put on a new patch, change the place where you put it (i.e., abdomen, hips or buttocks) if a patch falls off and you cannot press it back onto your skin, use a new patch How to dispose of a used patch: when you take off a used patch, fold it in half with the sticky sides together throw it away so that it cannot be worn or swallowed by another person, especially a child, or a pet
⚠️Warnings~2 min read▾
Warnings For external use only Frequent urination can also be caused by: urinary tract infections (UTI) diabetes early pregnancy other more serious conditions If you think you might have one of these conditions, it is important to see your doctor before use. Sleepiness, dizziness, confusion, and blurry vision may occur. Do not drive or operate machinery until you know how the patch affects you.
Do not use if you have any of these symptoms, which could be the sign of a UTI or other serious condition. See your doctor as soon as possible if you have: ○ pain or burning when urinating. These symptoms may also be accompanied by a fever or chills. ○ blood in your urine ○ unexplained lower back or side pain ○ urine that is cloudy, or foul-smelling ○ are male.
Your symptoms may be due to a more serious condition. ○ are under the age of 18. It is not known if it works or is safe in children. ○ only experience accidental urine loss when you cough, sneeze or laugh, you may have stress incontinence. This product will not work for that condition. ○ have been told by a doctor you have urinary retention (are not able to empty your bladder) ○ have been told by a doctor you have gastric retention (your stomach empties slowly after a meal) ○ have glaucoma ○ are allergic to oxybutynin Ask a doctor before use if you have symptoms of diabetes, such as: ○ excessive thirst ○ extreme hunger unexplained weight loss liver or kidney disease Ask a doctor or pharmacist before use if you are taking a prescription medication for overactive bladder taking any drugs that may cause sleepiness, dizziness, dry mouth, constipation or blurred vision taking certain antibiotics (for example, erythromycin, clarithromycin) or prescription antifungals (for example, ketoconazole, itraconazole) When using this product you may have itching, rash or redness where the patch was placed drinking alcohol may increase sleepiness Stop use and ask a doctor if you are not able to empty your bladder (urinary retention) condition worsens, or if new symptoms appear condition does not improve after 2 weeks of use you have an allergic reaction to this product you have severe redness, itchiness or blistering at the site of application If pregnant or breastfeeding, ask a health professional before use.
Keep out of reach of children. If swallowed, get medical help or contact a Poison Control Center right away.
🧪Active Ingredient10 words▾
Active ingredient (in each patch [transdermal system]) Oxybutynin 3.9 mg/day
For educational and professional reference only — not medical advice. Pricing reflects published
NADAC and CMS ASP (free public data) and may differ from your acquisition cost; always verify before billing or dispensing.
